Ann Dermatol.  2017 Aug;29(4):433-437. 10.5021/ad.2017.29.4.433.

Various Dermatoses What the Patients with Cutaneous Melanoma Had Anxiety for the Recurrence during Postoperative Surveillance

• Lee HJ
• Jin H
• You HS
• Shim WH
• Kim JM
• Kim GW
• Mun JH
• Kim HS
• Ko HC
• Kim BS
• Kim MB

• KMID: 2388941
• DOI: http://doi.org/10.5021/ad.2017.29.4.433

Abstract

BACKGROUND
The incidence and mortality rates associated with cutaneous melanoma (CM) have steadily increased over the last 20 years. Even with successful treatment, melanoma patients usually experience substantial anxiety regarding the development of terrible recurrence. To date, few studies have investigated various dermatoses what the patients with CM had anxiety for the recurrence during postoperative surveillance (Dw).
OBJECTIVE
To describe various Dw and to evaluate the risk of subsequent malignant skin disease in patients with CM.
METHODS
We performed a prospective study between August 2002 and August 2015.
RESULTS
Fifty-six patients presented with a total of 68 Dw. Among them, melanocytic nevus was the most common (n=27), followed by seborrheic keratosis (n=9) and CM recurrence (n=7). Approximately 5.6% of the lesions were diagnosed as malignant skin diseases. This was a single-center study, so the prevalence of malignant skin diseases following primary melanoma may not represent that of all patients with CM.
CONCLUSION
The results of this study can be referred by dermatologists dealing with melanoma especially when CM patients have too excessive or unrealistic anxiety for melanoma recurrence during postoperative surveillance of CM. However, the importance of postoperative surveillance must still be emphasized because of real risk of melanoma recurrence and other malignant skin.

Keyword

Melanomas; Postoperative surveillance

MeSH Terms

Anxiety*
Humans
Incidence
Keratosis, Seborrheic
Melanoma*
Mortality
Nevus, Pigmented
Prevalence
Prospective Studies
Recurrence*
Skin
Skin Diseases*

Figure

• 

  Fig. 1 Onsets of dermatoses what the patients with cutaneous melanoma (CM) had anxiety for the recurrence during postoperative surveillance. Dw: dermatoses what the patients with CM had anxiety for the recurrence during postoperative surveillance.

Reference

1. Ministry of Health and Welfare. Cancer incident cases, incidence rates and relative survival rate. Statistics Korea [Internet]. Daejeon: Statistics Korea;2012. Available from: http://kosis.kr.

2. Korean Statistical Information Service. Cause of death statistics. Statistics Korea [Internet]. Daejeon: Statistics Korea;2014. Available from: http://kosis.kr.

3. Stang A, Stang K, Stegmaier C, Hakulinen T, Jöckel KH. Skin melanoma in Saarland: incidence, survival and mortality 1970-1996. Eur J Cancer Prev. 2001; 10:407–415.

4. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer. 2000; 89:1269–1278.

5. van der Velden HM, van Rossum MM, Blokx WA, Boezeman JB, Gerritsen MJ. Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. Dermatol Res Pract. 2009; 2009:479183.

6. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, et al. Melanoma. J Natl Compr Canc Netw. 2009; 7:250–275.

7. Dancey A, Rayatt S, Courthold J, Roberts J. Views of UK melanoma patients on routine follow-up care. Br J Plast Surg. 2005; 58:245–250.

8. Themstrup L, Jemec GE, Lock-Andersen J. Patients highly value routine follow-up of skin cancer and cutaneous melanoma. Dan Med J. 2013; 60:A4713.

9. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 1987; 17:459–468.

10. Garbe C, Büttner P, Weiss J, Soyer HP, Stocker U, Krüger S, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol. 1994; 102:695–699.

11. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997; 277:1439–1444.

12. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003; 139:282–288.

13. Cruse CW, Wells KE, Schroer KR, Reintgen DS. Etiology and prognosis of local recurrence in malignant melanoma of the skin. Ann Plast Surg. 1992; 28:26–28.

14. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer. 1985; 55:1398–1402.

15. Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cancer. 1997; 80:1418–1425.

16. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996; 73:255–259.

17. Veronesi U, Cascinelli N, Bufalino R. Evaluation of the risk of multiple primaries in malignant cutaneous melanoma. Tumori. 1976; 62:127–130.

18. Brobeil A, Rapaport D, Wells K, Cruse CW, Glass F, Fenske N, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997; 4:19–23.

19. DiFronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999; 6:705–711.

20. Jung GW, Dover DC, Salopek TG. Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. Br J Dermatol. 2014; 170:136–143.

21. Korta DZ, Saggar V, Wu TP, Sanchez M. Racial differences in skin cancer awareness and surveillance practices at a public hospital dermatology clinic. J Am Acad Dermatol. 2014; 70:312–317.

22. Korfage IJ, Essink-Bot ML, Janssens AC, Schröder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer. 2006; 94:1093–1098.